A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Recruiting

• Conditions: Plaque Psoriasis
• Interventions: Drug: TAK-279

• Registration Number: NCT06550076
• Lead Sponsor: Takeda

Brief Summary

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Detailed Description

This study consists of 2 parts: Part A and Part B.

Part A: Participants who did not participate in either parent study (TAK-279-3001 \[NCT06088043\] or TAK-279-3002 \[NCT06108544\]) may be enrolled and will be treated for up to 52 weeks. Participants who successfully complete Part A of the study are eligible to continue in Part B, but investigators must confirm their eligibility to continue in Part B.

Part B: Participants who complete the treatment period of TAK-279-3001 (NCT06088043) or TAK-279-3002 (NCT06108544) parent studies or who complete Part A are eligible to enroll directly into open label extension treatment in Part B and will be treated for up to 156 weeks.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2024-08-08
• Study First Submitted QC: 2024-08-08
• Study First Posted: 2024-08-12
• Study Start: 2024-09-04
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-20
• Last Update Posted: 2024-12-27
• Primary Completion: 2026-05-07
• Study Completion: 2026-05-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1300

Inclusion Criteria

Part A:

• Participant is willing and able to understand and fully comply with study procedures and requirements (including digital tools and applications), in the opinion of the investigator.
• Participant has provided written informed consent and any required privacy authorization before the initiation of any study procedures.
• Participant is aged 18 years or older at the time of consent.
• Participant has a diagnosis of chronic plaque psoriasis for >=6 months prior to the screening visit.
• Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for >=6 months before screening.
• Participant has moderate-to-severe plaque psoriasis as defined by a PASI score >=12 and a sPGA score >=3 at screening and Day 1.
• Participant has plaque psoriasis covering >=10% of his or her total BSA at screening and Day 1.
• Participant must be a candidate for phototherapy or systemic therapy.

Part B:

• Participant has completed 52 weeks of treatment (TAK-279-3001 or Part A) or 60 weeks of treatment (TAK-279-3002) in their parent study or Part A.

Main Exclusion Criteria

Part A:

• Participant has evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary.

• Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune-related disease (e.g., inflammatory bowel disease).

• Participant has any clinically significant medical condition, evidence of an unstable clinical condition (e.g., cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. These include but are not limited to:

  1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy.
  2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the study.
  3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.
  4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria.
  5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
  6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.
  7. Participant has any of the following cardiovascular disease history: A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, non-acute cardiac hospitalization (e.g., pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll.
  8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the study, in the opinion of the investigator.
  9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator.
  10. Participant has any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by 1) medical history; or 2) by Columbia-Suicide Severity Rating Scale (C-SSRS) documentation at screening or by answering "yes" to Question 5 for suicidal ideation on the C-SSRS at screening; or 3) is clinically deemed to have a suicide risk by the investigator.
  11. Participant has a patient health questionnaire - 8 (PHQ-8) score of 15 or above at screening.
  12. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1.

• Participant has received any of the following biologics or biosimilar versions within the time frame indicated or 5 half-lives, whichever is longer:

  1. Antibodies to interleukin (IL) -12/-23, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1.
  2. Tumor necrosis factor inhibitor(s) (e.g., etanercept, adalimumab, infliximab, certolizumab) within 2 months prior to Day 1.
  3. Agents that modulate integrin pathways to impact lymphocyte trafficking (e.g., natalizumab) or agents that modulate B cells or T cells (e.g., alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1.
  4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1.

• Participant has any previous exposure to TAK-279 (also known as NDI-034858) or other TYK2 inhibitors, including deucravacitinib, or participant participated in any study that included a TYK2 inhibitor (e.g., deucravacitinib, VTX958, GLPG3667, etc.), unless the participant has documentation of post-trial unblinding that confirms the partcipant did not receive a TYK2 inhibitor.

• Participant has a known or suspected allergy to TAK-279 or any of its components.

Part B:

• Participant has completed the parent study or Part A but was permanently discontinued from treatment.
• Participant had evidence of significant noncompliance with study visits or study drug in the parent study or Part A, as defined in the parent study protocol or in the opinion of the investigator.
• Participant has met criteria for termination from the parent study or Part A, regardless of whether or not the participant was terminated from the parent study or Part A.
• Participant has developed evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis) since enrollment in the parent study or Part A.
• Participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments.
• Participant has received a prohibited psoriasis treatment during the parent study or Part A, whether or not that treatment was documented as a concomitant medication and is expected to continue that treatment.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Part A (De Novo Cohort) + Part B (Open Label Extension): TAK-279	TAK-279	Part A: Participants will receive TAK-279, oral tablet once daily (QD) for up to 52 weeks. Part B: Participants who completed the treatment period of parent studies (TAK-279-3001 \[NCT06088043\] or TAK-279-3002 \[NCT06108544\]) or who completed Part A will receive TAK-279, oral tablet QD for up to 156 weeks.

Primary Outcome Measures

Name	Time	Method
Part A and Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)	From start of the drug administration up to Week 56 (Part A) and Week 160 (Part B)	A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. TEAEs consist of both serious and non-serious adverse events.

Secondary Outcome Measures

Name	Time	Method
Part A and B: Number of Participants Achieving 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI-75) Score	Baseline up to Week 52 (Part A) and Week 156 (Part B)	The PASI is a composite score based on the degree of effect on body surface area of psoriasis and extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. The PASI-75 is defined as 75% improvement from baseline in PASI score.
Part A and B: Number of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a >=2-point Decrease from Baseline	Baseline up to Week 52 (Part A) and Week 156 (Part B)	The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA composite score ranges from 0 to 4 and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean greater than (\>) 0, less than (\<) 1.5; Mild (2) = mean greater than or equal to (\>=) 1.5, \<2.5; Moderate (3) = mean \>=2.5, \<3.5; and Severe (4) = mean \>=3.5.

Trial Locations

Locations (280)

Total Dermatology; 🇺🇸 Birmingham, Alabama, United States

University of Alabama Hospital - Whitaker Clinic -; 🇺🇸 Birmingham, Alabama, United States

Cahaba Dermatology Skin Health Center; 🇺🇸 Hoover, Alabama, United States

Medical Dermatology Specialists; 🇺🇸 Phoenix, Arizona, United States

Saguaro Dermatology Associates, LLC - Probity - PPDS; 🇺🇸 Phoenix, Arizona, United States

Noble Clinical Research; 🇺🇸 Tucson, Arizona, United States

Johnson Dermatology Clinic; 🇺🇸 Fort Smith, Arkansas, United States

Burke Pharmaceutical Research; 🇺🇸 Hot Springs, Arkansas, United States

Zenith Research, Inc.; 🇺🇸 Beverly Hills, California, United States

First OC Dermatology Research Inc.; 🇺🇸 Fountain Valley, California, United States

Center for Dermatology Clinical Research; 🇺🇸 Fremont, California, United States

Long Beach Research Institute; 🇺🇸 Long Beach, California, United States

Metropolis Dermatology Downtown LA - Probity - PPDS; 🇺🇸 Los Angeles, California, United States

UCLA University of California Los Angeles; 🇺🇸 Los Angeles, California, United States

Northridge Clinical Trials; 🇺🇸 Northridge, California, United States

UC Davis Dermatology Clinic; 🇺🇸 Sacramento, California, United States

TCR Medical Corporation; 🇺🇸 San Diego, California, United States

University Clinical Trials; 🇺🇸 San Diego, California, United States

Dermatology Institute and Skin Care Center; 🇺🇸 Santa Monica, California, United States

UNISON Clinical Trials (Shahram Jacobs md inc.); 🇺🇸 Sherman Oaks, California, United States

Driven Research LLC; 🇺🇸 Coral Gables, Florida, United States

Revival Research Corporation - Florida - ClinEdge - PPDS; 🇺🇸 Doral, Florida, United States

FXM Clinical Research Ft. Lauderdale, LLC; 🇺🇸 Fort Lauderdale, Florida, United States

Direct Helpers Medical Center; 🇺🇸 Hialeah, Florida, United States

San Marcus Research Clinic Inc; 🇺🇸 Miami Lakes, Florida, United States

Florida Academic Centers Research; 🇺🇸 Miami, Florida, United States

FXM Clinical Research Miami, LLC; 🇺🇸 Miami, Florida, United States

FXM Research Miramar; 🇺🇸 Miramar, Florida, United States

Renstar Medical Research -21 NE 1st Ave; 🇺🇸 Ocala, Florida, United States

Lenus Research & Medical Group; 🇺🇸 Sweetwater, Florida, United States

Advanced Clinical Research Institute (ACRI) - Florida; 🇺🇸 Tampa, Florida, United States

Divine Dermatology and Aesthetics, LLC; 🇺🇸 Atlanta, Georgia, United States

Marietta Dermatology & The Skin Cancer Center - Marietta; 🇺🇸 Marietta, Georgia, United States

Advanced Medical Research, PC; 🇺🇸 Sandy Springs, Georgia, United States

Georgia Skin and Cancer Clinic; 🇺🇸 Savannah, Georgia, United States

Leavitt Clinical Research; 🇺🇸 Idaho Falls, Idaho, United States

Arlington Dermatology; 🇺🇸 Rolling Meadows, Illinois, United States

NorthShore Medical Group Dermatology - Skokie; 🇺🇸 Skokie, Illinois, United States

DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location; 🇺🇸 Clarksville, Indiana, United States

Dawes Fretzin Clinical Research Group, LLC; 🇺🇸 Indianapolis, Indiana, United States

Skin Sciences, PLLC; 🇺🇸 Louisville, Kentucky, United States

Dermatology Specialists Research - 3810 Springhurst Blvd; 🇺🇸 Louisville, Kentucky, United States

Lawrence J Green, MD LLC; 🇺🇸 Rockville, Maryland, United States

University of Michigan Hospital - 1500 E Medical Center Dr; 🇺🇸 Ann Arbor, Michigan, United States

Oakland Hills Dermatology - 3400 Auburn Rd; 🇺🇸 Auburn Hills, Michigan, United States

Revival Research Corporation - ClinEdge; 🇺🇸 Troy, Michigan, United States

Minnesota Clinical Study Center; 🇺🇸 New Brighton, Minnesota, United States

Skin Specialists PC; 🇺🇸 Omaha, Nebraska, United States

Henderson Clinical Trials; 🇺🇸 Henderson, Nevada, United States

Dartmouth Hitchcock Medical Center - Old Etna Rd; 🇺🇸 Lebanon, New Hampshire, United States

ALLCUTIS Research, LLC.; 🇺🇸 Portsmouth, New Hampshire, United States

Psoriasis Treatment Center of Central New Jersey; 🇺🇸 East Windsor, New Jersey, United States

Montefiore AOA - BRANY; 🇺🇸 Bronx, New York, United States

Sadick Research Group; 🇺🇸 New York, New York, United States

Derm Research Center of NY; 🇺🇸 Stony Brook, New York, United States

Accellacare of Cary; 🇺🇸 Cary, North Carolina, United States

The Skin Surgery Center for Clinical Research - Objective Health - PPDS; 🇺🇸 Winston-Salem, North Carolina, United States

Bexley Dermatology Research - Probity - PPDS; 🇺🇸 Bexley, Ohio, United States

Wright State Physicians; 🇺🇸 Fairborn, Ohio, United States

Apex Clinical Research Center; 🇺🇸 Mayfield Heights, Ohio, United States

Oregon Medical Research Center PC; 🇺🇸 Portland, Oregon, United States

University of Pittsburgh Medical Center-3601 5th Ave; 🇺🇸 Pittsburgh, Pennsylvania, United States

Cumberland Skin Center for Clinical Research - Objective Health - PPDS; 🇺🇸 Hermitage, Tennessee, United States

International Clinical Research US LLC; 🇺🇸 Murfreesboro, Tennessee, United States

Arlington Research Center; 🇺🇸 Arlington, Texas, United States

Bellaire Dermatology Associates; 🇺🇸 Bellaire, Texas, United States

UT Physicians Dermatology - Bellaire Station; 🇺🇸 Bellaire, Texas, United States

Modern Research Associates; 🇺🇸 Dallas, Texas, United States

North Texas Center for Clinical Research; 🇺🇸 Frisco, Texas, United States

San Antonio; 🇺🇸 San Antonio, Texas, United States

Texas Dermatology and Laser Specialists-San Antonio-7703 Floyd Curl Dr; 🇺🇸 San Antonio, Texas, United States

Dermatology Clinical Research Center of San Antonio; 🇺🇸 San Antonio, Texas, United States

Houston Center for Clinical Research, LLC; 🇺🇸 Sugar Land, Texas, United States

Center For Clinical Studies, LTD. LLP - 451 N Texas Ave; 🇺🇸 Webster, Texas, United States

Virginia Clinical Research - 6160 Kempsville Cir; 🇺🇸 Norfolk, Virginia, United States

Conexa Investigación Clínica S.A.; 🇦🇷 Ciudad Autónoma de Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina

Centro de Investigaciones Médicas Tucumán; 🇦🇷 San Miguel de Tucuman, Tucumán, Argentina

Instituto de Dermatología y Neumonología; 🇦🇷 Buenos Aires, Argentina

Centro de Investigacion Clinica; 🇦🇷 Ciudad Autónomade Buenos Aires, Argentina

St George Dermatology and Skin Cancer Center - Probity - Probity; 🇦🇺 Kogarah, New South Wales, Australia

The Skin Center - Probity; 🇦🇺 Benowa, Queensland, Australia

Skin Health Institute Inc - Probity - PPDS; 🇦🇺 Carlton, Victoria, Australia

Sinclair Dermatology-East Melbourne; 🇦🇺 East Melbourne, Victoria, Australia

Alfred Health; 🇦🇺 Parkville, Victoria, Australia

Western Health - Sunshine Hospital; 🇦🇺 Parkville, Victoria, Australia

Medical Center Unimed EOOD-Sevlievo; 🇧🇬 Sevlievo, Gabrovo, Bulgaria

Medical Center Asklepii OOD; 🇧🇬 Dupnitsa, Kjustendil, Bulgaria

Diagnostic and Consulting Center Aleksandrovska EOOD; 🇧🇬 Sofia, Sofia-Grad, Bulgaria

Diagnostic Consultative Centre - Focus-5 - LZIP EOOD; 🇧🇬 Sofia, Sofia-Grad, Bulgaria

Medical Center Hera EOOD-Sofia; 🇧🇬 Sofia, Sofia-Grad, Bulgaria

Diagnostic Consultative Center XXVIII - Sofia - EOOD; 🇧🇬 Sofia, Sofia-Grad, Bulgaria

Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia; 🇧🇬 Sofia, Sofia-Grad, Bulgaria

MC Comac Medical; 🇧🇬 Sofia, Sofia-Grad, Bulgaria

Multiprofile Hospital For Active Treatment Dr Tota Venkova; 🇧🇬 Gabrovo, Bulgaria

Diagnostic Consultative Center Sveti; 🇧🇬 Haskovo, Bulgaria

Medical Center Medconsult Pleven OOD; 🇧🇬 Pleven, Bulgaria

Beacon Dermatology - Probity; 🇨🇦 Calgary, Alberta, Canada

Dermatology Research Institute, Inc.; 🇨🇦 Calgary, Alberta, Canada

Alberta DermaSurgery Centre - Probity; 🇨🇦 Edmonton, Alberta, Canada

VIDA Dermatology - Probity; 🇨🇦 Edmonton, Alberta, Canada

Care Clinic; 🇨🇦 Red Deer, Alberta, Canada

Enverus Medical Research - Probity; 🇨🇦 Surrey, British Columbia, Canada

Wiseman Dermatology Research Inc.; 🇨🇦 Winnipeg, Manitoba, Canada

Karma Clinical Trials; 🇨🇦 St. John's, Newfoundland and Labrador, Canada

CCA Medical Research - Probity; 🇨🇦 Ajax, Ontario, Canada

SimcoDerm Medical and Surgical Dermatology Centre - Probity; 🇨🇦 Barrie, Ontario, Canada

Kingsway Clinical Research - Probity; 🇨🇦 Etobicoke, Ontario, Canada

Guelph Dermatology Research - Probity; 🇨🇦 Guelph, Ontario, Canada

Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity; 🇨🇦 Hamilton, Ontario, Canada

Dermatrials Research; 🇨🇦 Hamilton, Ontario, Canada

Mediprobe Research Inc; 🇨🇦 London, Ontario, Canada

DermEffects; 🇨🇦 London, Ontario, Canada

Lynderm Research Inc - Probity; 🇨🇦 Markham, Ontario, Canada

DermEdge Research - Probity; 🇨🇦 Mississauga, Ontario, Canada

Dr. S. K. Siddha Medicine Professional Corporation | Newmarket, Canada; 🇨🇦 Newmarket, Ontario, Canada

North Bay Dermatology Center - Probity; 🇨🇦 North Bay, Ontario, Canada

The Centre for Clinical Trials Inc.; 🇨🇦 Oakville, Ontario, Canada

Skin Centre for Dermatology; 🇨🇦 Peterborough, Ontario, Canada

The Centre For Dermatology; 🇨🇦 Richmond Hill, Ontario, Canada

North York Research Inc. - Probity; 🇨🇦 Toronto, Ontario, Canada

Canadian Dermatology Centre - Probity; 🇨🇦 Toronto, Ontario, Canada

Toronto Research Centre; 🇨🇦 Toronto, Ontario, Canada

Toronto Research Centre - Probity; 🇨🇦 Toronto, Ontario, Canada

Alliance Clinical Trials; 🇨🇦 Waterloo, Ontario, Canada

XLR8 Medical Research; 🇨🇦 Windsor, Ontario, Canada

Siena Medical Research Corporation; 🇨🇦 Montreal, Quebec, Canada

Skinsense Medical Research - Probity; 🇨🇦 Saskatoon, Saskatchewan, Canada

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China

Beijing Friendship Hospital, Capital Medical University; 🇨🇳 Beijing, Beijing, China

Peking University Third Hospital; 🇨🇳 Beijing, Beijing, China

Beijing Tongren Hospital, Capital Medical University; 🇨🇳 Beijing, Beijing, China

The First Affiliated Hospital of Chongqing Medical University; 🇨🇳 Chongqing, Chongqing, China

The First Affiliated Hospital of Fujian Medical University; 🇨🇳 Fuzhou, Fujian, China

Guangdong Provincial People's Hospital; 🇨🇳 Guangzhou, Guangdong, China

Dermatology Hospital of Southern Medical University; 🇨🇳 Guangzhou, Guangdong, China

Sun Yat-sen Memorial Hospital, Sun Yat-sen University; 🇨🇳 Guangzhou, Guangdong, China

Zhujiang Hospital of Southern Medical University; 🇨🇳 Guangzhou, Guangdong, China

The First Hospital of Hebei Medical University; 🇨🇳 Shijiazhuang, Hebei, China

Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST); 🇨🇳 Wuhan, Hubei, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology; 🇨🇳 Wuhan, Hubei, China

Renmin Hospital of Wuhan University; 🇨🇳 Wuhan, Hubei, China

Affiliated Hospital of Jiangsu University; 🇨🇳 Zhenjiang, Jiangsu, China

Huashan Hospital Fudan University - PPDS; 🇨🇳 Shanghai, Minhang District, China

General Hospital of Ningxia Medical University; 🇨🇳 Yinchuan, Ningxia, China

Shandong Provincial Hospital; 🇨🇳 Jinan, Shandong, China

Shanghai Skin Disease Hospital; 🇨🇳 Shanghai, Shanghai, China

First Hospital of Shanxi Medical University; 🇨🇳 Taiyuan, Shanxi, China

The 2nd Hospital of Xi'An Jiaotong University; 🇨🇳 Xi'an, Shanxi, China

West China Hospital Sichuan University; 🇨🇳 Chengdu, Sichuan, China

Zhejiang Provincial People's Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Sir Run Run Shaw Hospital Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China

The 1st Affiliated Hospital of Wenzhou Medical University; 🇨🇳 Wenzhou, Zhejiang, China

The University of Hong Kong - Shenzhen Hospital; 🇨🇳 Shenzhen, China

Pratia Brno s.r.o. - PRATIA - PPDS; 🇨🇿 Brno, Jihomoravský Kraj, Czechia

Dermamedica, s.r.o. - Kozni Ambulance Nachod; 🇨🇿 Nachod, Královéhradecký Kraj, Czechia

Nemocnice AGEL Novy Jicin a.s; 🇨🇿 Nový Jičín, Moravskoslezský Kraj, Czechia

CCR Ostrava s.r.o.; 🇨🇿 Ostrava, Moravskoslezský Kraj, Czechia

Dermskin s.r.o; 🇨🇿 Olomouc, Olomoucký Kraj, Czechia

Pratia Pardubice a.s. - PRATIA - PPDS; 🇨🇿 Pardubice, Pardubický Kraj, Czechia

Praglandia; 🇨🇿 Prague, Czechia

CLINTRIAL s.r.o.; 🇨🇿 Praha 10, Czechia

Fakultni nemocnice Kralovske Vinohrady; 🇨🇿 Praha 10, Czechia

Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS; 🇨🇿 Praha 1, Czechia

Hautarztpraxis Mahlow; 🇩🇪 Blankenfelde-Mahlow, Brandenburg, Germany

Fachklinik Bad Bentheim; 🇩🇪 Bad Bentheim, Niedersachsen, Germany

Klinikum Oldenburg; 🇩🇪 Oldenburg, Niedersachsen, Germany

Universitatsklinikum Munster; 🇩🇪 Münster, Nordrhein-Westfalen, Germany

Klinische Forschung Dresden Gmbh; 🇩🇪 Dresden, Sachsen, Germany

Praxis fur Dermatologie and Venerologie; 🇩🇪 Dresden, Sachsen, Germany

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck; 🇩🇪 Lübeck, Schleswig Holstein, Germany

SRH Wald-Klinikum Gera GmbH; 🇩🇪 Gera, Thüringen, Germany

Dermatologikum Hamburg; 🇩🇪 Hamburg, Germany

Allergo-Derm Bakos Kft.; 🇭🇺 Szolnok, Jász-Nagykun-Szolnok, Hungary

Somogy Megyei Kaposi Mór Oktató Kórház; 🇭🇺 Kaposvár, Somogy, Hungary

Markusovszky Egyetemi Oktatókórház; 🇭🇺 Szombathely, Vas, Hungary

Debreceni Egyetem; 🇭🇺 Debrecen, Hungary

Rabin Medical Center - PPDS; 🇮🇱 Petach Tikva, Israel

Chaim Sheba Medical Center; 🇮🇱 Ramat Gan, Israel

IRCCS Istituto Clinico Humanitas; 🇮🇹 Rozzano, Milano, Italy

Presidio Ospedaliero Gaspare Rodolico; 🇮🇹 Catania, Sicilia, Italy

Azienda Usl Toscana Centro - Firenze; 🇮🇹 Firenze, Toscana, Italy

Nagoya City University Hospital; 🇯🇵 Nagoya-City, Aichi, Japan

Takagi Dermatological Clinic; 🇯🇵 Obihiro-Shi, Hokkaidô, Japan

JR Sapporo Hospital; 🇯🇵 Sapporo-Shi, Hokkaidô, Japan

Medical Corporation Kojinkai Sapporo Skin Clinic; 🇯🇵 Sapporo-Shi, Hokkaidô, Japan

Fukuoka University Hospital; 🇯🇵 Fukuoka-Shi, Hukuoka, Japan

Saruwatari Dermatology Clinic; 🇯🇵 Kagoshima-Shi, Kagosima, Japan

Jichi Medical University Hospital; 🇯🇵 Shimotsuke-shi, Tochigi-Ken, Japan

JCHO Tokyo Yamate Medical Center; 🇯🇵 Shinjuku-ku, Tokyo-To, Japan

Tokyo Teishin Hospital; 🇯🇵 Sumida-Ku, Tokyo, Japan

Ohyama Dermatology Clinic; 🇯🇵 Kumamoto, Japan

Tokyo Medical University Hospital; 🇯🇵 Tokyo, Japan

Dermatology and Ophthalmology Kume Clinic; 🇯🇵 Sakai-Shi, Ôsaka, Japan

Yonsei University Wonju Severance Christian Hospital; 🇰🇷 Wonju-si, Gangwon-do, Korea, Republic of

Chosun University Hospital; 🇰🇷 Gwangju, Gwangju Gwang'yeogsi, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Beon-gil Bundang-gu, Gyeonggi-do, Korea, Republic of

The Catholic University of Korea, Bucheon St. Mary's Hospital; 🇰🇷 Bucheon-si, Gyeonggido, Korea, Republic of

CHA Bundang Medical Center, CHA University; 🇰🇷 Seongnam-Si, Gyeonggido, Korea, Republic of

Konkuk University Medical Center; 🇰🇷 Gwangjin-Gu, Seoul Teugbyeolsi, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital; 🇰🇷 Seocho-Gu, Seoul Teugbyeolsi, Korea, Republic of

Soon Chun Hyang University Hospital Seoul; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Kyung Hee University Hospital; 🇰🇷 Seoul, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Chung-Ang University Hospital; 🇰🇷 Seoul, Korea, Republic of

Smite Aija medical practice in dermatology, venerology; 🇱🇻 Talsi, Talsu Aprinkis, Latvia

Semigallia; 🇱🇻 Kuldīga, Latvia

Riga 1st Hospital; 🇱🇻 Riga, Latvia

Aesthetic dermatology clinic of prof. J. Kisis; 🇱🇻 Riga, Latvia

Health Center 4-1 Grebenscikova Str; 🇱🇻 Riga, Latvia

Veseliba un estetika Ltd.; 🇱🇻 Riga, Latvia

Outpatient Clinic Adoria; 🇱🇻 Riga, Latvia

Health Center 4-Skanstes iela 50; 🇱🇻 Riga, Latvia

Centrum Medyczne Katowice - PRATIA; 🇵🇱 Katowice, Dolnoslaskie, Poland

Globe Badania Kliniczne Spolka z o.o. - Klodzko; 🇵🇱 Klodzko, Dolnoslaskie, Poland

Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p; 🇵🇱 Wroclaw, Dolnoslaskie, Poland

Velocity Skierniewice Sp. z o.o.; 🇵🇱 Skierniewice, Lodzkie, Poland

Dermoklinika-Centrum Medyczne s.c; 🇵🇱 Łódź, Lodzkie, Poland

Clinical Best Solutions Sp. z o.o. S.K.; 🇵🇱 Warszawa, Mazowieckie, Poland

Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska; 🇵🇱 Lublin, Lubelskie, Poland

Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A.; 🇵🇱 Lódz, Lódzkie, Poland

Centrum Medyczne ALL-MED; 🇵🇱 Krakow, Malopolskie, Poland

Pratia MCM Krakow; 🇵🇱 Krakow, Malopolskie, Poland

Krakowskie Centrum Medyczne Sp. z o.o.; 🇵🇱 Kraków, Malopolskie, Poland

Rheumatology Clinic NZOZ Lecznica MAK-MED; 🇵🇱 Nadarzyn, Mazowieckie, Poland

ETG Siedlce - PPDS; 🇵🇱 Siedlce, Mazowieckie, Poland

RCMed Oddzial Sochaczew; 🇵🇱 Sochaczew, Mazowieckie, Poland

Klinika Reuma Park sp . zoo Sp.k.; 🇵🇱 Warsaw, Mazowieckie, Poland

MICS Centrum Medyczne Warszawa; 🇵🇱 Warszawa, Mazowieckie, Poland

Clinical Research Group Sp. z o.o; 🇵🇱 Warszawa, Mazowieckie, Poland

High-Med Przychodnia Specjalistyczna; 🇵🇱 Warszawa, Mazowieckie, Poland

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie; 🇵🇱 Warszawa, Mazowieckie, Poland

ETG Warszawa - PPDS; 🇵🇱 Warszawa, Mazowieckie, Poland

Klinika Ambroziak Dermatologia; 🇵🇱 Warszawa, Mazowieckie, Poland

FutureMeds - Targowek - PPDS; 🇵🇱 Warszawa, Mazowieckie, Poland

NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik; 🇵🇱 Bialystok, Podlaskie, Poland

ClinicMed Daniluk, Nowak Spolka Komandytowa; 🇵🇱 Bialystok, Podlaskie, Poland

Centrum Medyczne Chojnice - PRATIA - PPDS; 🇵🇱 Chojnice, Pomorskie, Poland

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku; 🇵🇱 Gdansk, Pomorskie, Poland

Copernicus Podmiot Leczniczy Sp. z o.o, Szpital Sw. Wojciecha, Oddzial Dermatologii; 🇵🇱 Gdansk, Pomorskie, Poland

Centrum Badan Klinicznych Pi-house Sp. Z O. O.; 🇵🇱 Gdansk, Pomorskie, Poland

Derm-art; 🇵🇱 Gdynia, Pomorskie, Poland

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Katowicach; 🇵🇱 Katowice, Slaskie, Poland

Centrum Medyczne Angelius Provita; 🇵🇱 Katowice, Slaskie, Poland

Pro Familia Altera Sp. z o.o.; 🇵🇱 Katowice, Slaskie, Poland

Dermedic Jacek Zdybski; 🇵🇱 Ostrowiec Swietokrzyski, Swietokrzyskie, Poland

Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.; 🇵🇱 Ostrowiec Swietokrzyski, Swietokrzyskie, Poland

Solumed Centrum Medyczne; 🇵🇱 Poznan, Wielkopolskie, Poland

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu; 🇵🇱 Poznan, Wielkopolskie, Poland

Twoja Przychodnia PCM; 🇵🇱 Poznań, Wielkopolskie, Poland

Twoja Przychodnia Szczecińskie Centrum Medyczne Sp. z o.o.; 🇵🇱 Szczecin, Zachodniopomorskie, Poland

Centrum Uslug Medycznych MaxMed; 🇵🇱 Bochnia, Poland

Centrum Medyczne Bydgoszcz- PRATIA; 🇵🇱 Bydgoszcz, Poland

Ambulatorium Sp. z o.o.; 🇵🇱 Elblag, Poland

Promed P. Lach R. Głowacki Sp. j., Centrum Medyczne Promed; 🇵🇱 Krakow, Poland

Diamond Clinic Sp. z o.o., Diamond Medical Center; 🇵🇱 Krakow, Poland

Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Lodzi, Klinika Dermatologii i Wenerologii; 🇵🇱 Lodz, Poland

Pro Life Medica Sp. z o.o. ETG Lublin; 🇵🇱 Lublin, Poland

Twoja Przychodnia - Nowosolskie Centrum Medyczne sp. z o.o; 🇵🇱 Nowa Sól, Poland

ETYKA Osrodek Badan Klinicznych; 🇵🇱 Olsztyn, Poland

MICS Centrum Medyczne Torun; 🇵🇱 Torun, Poland

Royalderm Agnieszka Nawrocka; 🇵🇱 Warszawa, Poland

dermMEDICA Sp. z o.o. | Krzysztofa Kolumba 6; 🇵🇱 Wrocław, Poland

GCM Medical Group; 🇵🇷 San Juan, Puerto Rico

Hospital Clinico San Carlos; 🇪🇸 San Sebastian, Guipúzcoa, Spain

Hospital Universitario de Gran Canaria Doctor Negrin; 🇪🇸 Las Palmas de Gran Canaria, LAS Palmas, Spain

Hospital de Manises; 🇪🇸 Manises, Valencia, Spain

Hospital de La Santa Creu i Sant Pau - Dermatologia; 🇪🇸 Barcelona, Spain

National Cheng Kung University; 🇨🇳 Tainan, Tainan City, Taiwan

National Taiwan University Hospital, Hsin-Chu Branch; 🇨🇳 Hsinchu City, Taiwan

Kaohsiung Veterans General Hospital; 🇨🇳 Kaohsiung City, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei City, Taiwan

Mackay Memorial Hospital-Taipei branch; 🇨🇳 Taipei, Taiwan

National Taiwan University Hospital; 🇨🇳 Zhong Zheng Qu, Taiwan

Velocity Clinical Research - High Wycombe - PPDS; 🇬🇧 High Wycombe, Buckinghamshire, United Kingdom

4 Medical Clinical Solutions - Swinton - PPDS; 🇬🇧 Ilford, Essex, United Kingdom

Accellacare of Yorkshire; 🇬🇧 Chorley, Lancashire, United Kingdom

Salford Royal Hospital - PPDS; 🇬🇧 Salford, Lancashire, United Kingdom

Whipps Cross University Hospital; 🇬🇧 London, London, City Of, United Kingdom

Accellacare of Northamptonshire; 🇬🇧 Harrow, Middlesex, United Kingdom

Velocity Clinical Research North London - Percy Road - PPDS; 🇬🇧 London, Middlesex, United Kingdom